Image by Chemical Heritage Foundation via Flickr
While Merck’s net profits might be a little low in the wake of the Schering-Plough merger, it’s pipeline—and future sales—are far from bleak.
According to a new report from analyst firm Deutsche Bank, Merck has no less than 18 drugs in Phase III development, with three slated for launch within [...]
PharmExec Blog
Follow Us
RSS
Bookstore
Merck Shows Off Bevy of New Drugs